Chuangyebang was informed that recently, Tongyi Pharmaceutical, an international innovative pharmaceutical company with a dual-ligand drug conjugation technology platform (Bi-XDC), announced the completion of the B round of financing. This round of financing was led by Huimei Capital, Yuanfeng Capital, Agricultural Silver International, Yicun Capital and other co-investors, and old shareholders Tong and Yucheng continued to raise.
Tongyi Medicine is committed to the research and development of tumor-targeted bispecific-Ligand Drug Conjugate (bi-XDC) innovative drugs; including tumor-targeted highly active toxin (BESTTM), tumor-targeted protein degradation drugs ( C-PROTAC), and a more innovative immunomodulatory drug conjugate (bispecific ligand Immuno-Modulator Drug Conjugate, bi-IMDC).
The financing will be mainly used for the clinical development of Tongyi’s Bi-XDC pipeline, including CBP-1008 China’s key registration phase II clinical trial, CBP-1018 China-US clinical phase I/II trial, and CBP-1019 China-US clinical phase I clinical trial. Trials, CBP-8088 (C-PROTAC) Sino-US IND application, etc. The clinical advancement of multiple core pipelines marks the full-speed advancement of Tongyi Medicine’s R&D pipeline in the dual-ligand drug coupling technology platform (Bi-XDC).
Tongyi Medicine is located in the Biomedical Industrial Park of Suzhou Industrial Park. Since its establishment, Tongyi Medicine has been committed to the R&D and industrialization of dual-ligand drug conjugate (Bi-XDC) innovative drug pipelines. Currently, there are three technology platforms: BESTTM Technology Platform, C-PROTAC Technology Platform and Chronic Disease Technology Platform. Dual-ligand drug conjugation technology (Bi-XDC) is expected to overcome the existing druggability barriers of many molecules with good activity and open up new avenues for drug development.
At present, multiple pipelines of Tongyi Medicine have been successively advanced to the global clinical trial stage. Among them, CBP-1008 has been administered to more than 150 clinical patients. The clinical 1a/1b data of CBP-1008 will be released at international industry conferences such as World ADC and AACR in May 2022, and it has been successfully selected for the oral report of the 2022 ASCO conference. CBP-1008 is expected to enter the pivotal registration phase II clinical trial by the end of 2022; CBP-1018 has entered the clinical phase I phase, with positive data from the ramp-up trial; CBP-1019 is expected to submit a Sino-US IND within the year. Tongyi Medicine’s research pipeline is actively expanding in pan-tumor indications, as well as organ-targeted delivery and chronic disease treatment.
Dr. Huang Baohua, founder and CEO of Tongyi Medicine, said: “I am very pleased to join hands with investors such as Huiyi Capital to jointly promote the research and development process of dual-ligand conjugated drugs in this round, and thank the outstanding investors in this round for their recognition of Tongyi Medicine. and support. In fact, through CBP-1008, the design concept of our dual-ligand conjugated drug has been preliminarily verified in terms of efficacy, showing preliminary efficacy in a variety of gynecological tumors, verifying the specificity advantage of dual-targeting The funds raised in this round will focus on the advancement of drugs that have entered the clinic, with a view to entering the market faster. We hope that through our continuous innovation in drug research and development, we can provide new clinical options for patients around the world.”
Huimei Capital said: “Tongyi Pharmaceutical’s Bi-XDC pipeline is leading in global R&D progress, and is one of the innovative XDC technology platforms with the largest number of patients with positive clinical data in the world. CBP -1008 targets folate alpha receptor (FRα) and TRPV6, and has obtained potential best clinical data for the same target, and has the potential to be approved for marketing through key registration phase II clinical trials; CBP-1018, CBP-1019 and other follow-up pipelines also have Potential to become an internationally competitive drug with the same target; CBP-8088 has the potential to become the world’s first C-PROTAC drug to apply for IND. Huimei Capital is very much looking forward to the Tongyi Pharmaceutical Dual Ligand Drug Conjugation Technology Platform (Bi-XDC) The rapid advancement of the R&D pipeline and the active expansion of other pipelines under development.”
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Start -up in the investment world
This article is reprinted from: https://readhub.cn/topic/8i7Mx4uihkH
This site is for inclusion only, and the copyright belongs to the original author.